Women who have migraines with an aura should not be prescribed estrogen because of:

A. The interaction between triptans and estrogen, limiting migraine therapy choices: There is no significant pharmacologic interaction between triptans and estrogen that would limit migraine treatment. Triptans can still be used to manage acute migraine attacks, but the primary concern with estrogen use in migraine with aura is vascular risk rather than drug interactions. B. An increased incidence of migraines with the use of estrogen: While estrogen fluctuations can trigger migraines, the main contraindication for women with migraine with aura is not simply an increase in migraine frequency. Estrogen use may exacerbate symptoms, but the critical concern is the potential for serious vascular events, particularly ischemic stroke. C. An increased risk of stroke occurring with estrogen use: Women with migraine with aura have a baseline increased risk of ischemic stroke. Exogenous estrogen, whether in combined oral contraceptives or hormone therapy, further elevates this risk by promoting a prothrombotic state. It is recommended to avoid estrogen-containing therapy in these patients to minimize stroke risk. D. Patients with migraines may be prescribed estrogen without any concerns: Prescribing estrogen without consideration in patients with migraine with aura is contraindicated due to the heightened risk of thromboembolic events and stroke. Alternative non-estrogenic therapies are preferred to manage both contraception and menopausal symptoms safely.